Rapid Antigen Testing Market – Demand, Growth & Forecast 2023-2033

Rapid Antigen Testing Market Outlook (2023 to 2033)

As per Future Market Insights, the rapid antigen testing market is anticipated to attain a value pool of USD 24 billion by 2023-end. Demand for rapid antigen testing is expected to rise at a CAGR of 7.6% to USD 50 billion in 2033.

The rapid antigen testing market is a rapidly growing market that is expected to continue to expand over the coming years. Here are some of the prominent drivers, opportunities, and trends in the rapid antigen testing market

Data Points	Key Statistics
Expected Market Value in 2023	USD 24 billion
Projected Market Value in 2033	USD 50 billion
Growth Rate (2023 to 2033)	7.6% CAGR

Key Market Drivers

• Need for rapid testing: The COVID-19 pandemic has created a huge demand for rapid testing, as governments, businesses, and individuals look for ways to quickly identify infected individuals and prevent the spread of the virus. Rapid antigen tests provide results in as little as 15 minutes, making them an important tool in the fight against the pandemic.
• Ease of use: Rapid antigen tests are generally easy to administer and do not require specialized training or equipment. This makes them a useful tool in a variety of settings, including schools, workplaces, and healthcare facilities.
• Regulatory approval: Rapid antigen tests have received regulatory approval from a number of different regulatory agencies, including the US FDA, the European Union, and other national regulatory bodies. This has helped to increase the availability and adoption of rapid antigen testing.

Opportunities

• Expansion into new markets: Rapid antigen testing can be used to identify a range of viral infections, not just COVID-19. There is an opportunity for companies to expand their offerings to include tests for other viruses, such as influenza, RSV, and other respiratory viruses. This could create new revenue streams and broaden the market for rapid antigen testing.
• Development of new products: There are opportunities for companies to develop new products and improve existing ones, such as improving the accuracy and sensitivity of rapid antigen tests.

• Partnerships and collaborations: There are opportunities for companies to partner with other organizations, such as healthcare providers or governments, to develop and distribute rapid antigen tests.
• Increased adoption in non-COVID settings: Rapid antigen tests may be useful in diagnosing other types of viral infections, such as influenza or RSV. There are opportunities for companies to develop rapid antigen tests for these other viral infections, which could expand the market for these products.

Prevalent Trends

• Improving accuracy: Companies are working to improve the accuracy and sensitivity of rapid antigen tests, which could increase their usefulness and adoption in a wider range of settings.
• Multiplexing: Multiplexing is the ability to test for multiple pathogens at once, which could increase the efficiency and speed of testing. There are opportunities for companies to develop multiplexed rapid antigen tests for COVID-19 and other viral infections.
• Digital integration: There are opportunities to integrate rapid antigen testing with digital technologies, such as mobile apps or cloud-based platforms, which could streamline testing and reporting processes.
• At-home testing: There are opportunities for companies to develop rapid antigen tests that can be used at home, which could increase accessibility and convenience for users.

To sum up, the rapid antigen testing market is a rapidly growing market with many drivers, opportunities, and trends. The need for rapid microbiology testing, cost-effectiveness, ease of use, and regulatory approval are key drivers of growth in the market. There are opportunities to expand into new markets, develop new products, form partnerships and collaborations, and increase adoption in non-COVID settings. The trends in the market include improving accuracy, multiplexing, physical-digital integration, and at-home testing. As the COVID-19 pandemic continues, the rapid antigen testing market is expected to continue to grow and evolve.

The presence of antigens in the body normally triggers an immune response, produced when any foreign agent enters into the body. These agents can be disease-causing microbes such as parasites, fungi, bacteria and other substances such as pollen.

Rapid antigen testing is used to detect antigen of various diseases, most common disease are influenza, malaria and streptococcal sore throat. A rapid antigen testing is a diagnostic test used in the medical emergency that detects the presence or absence of an antigen in the body.

Rapid antigen testing market is expected to grow rapidly over the forecast period with the increasing prevalence of infectious diseases and rising demand for early detection of the diseases. The outbreak of novel coronavirus is believed to have an enduring impact on rapid antigen testing market.

The rapid antigen testing is to be used in specified settings and kits for managing COVID-19 emergency. Scientists are trying to do advancement in the techniques that can provide quick and more accurate results.

The advanced techniques will influence the growth of the rapid antigen testing market post coronavirus pandemic also. Due to the increasing number of coronavirus patients, every part of the world is acquiring rapid antigen testing kit for conducting tests in the region, which in turn is boosting the rapid antigen testing market.

Rapid Antigen Testing Market: Drivers and Restraints

The rapid antigen testing market is growing due to the increasing prevalence of autoimmune diseases and sexually transmitted diseases along with the increasing awareness regarding early diagnosis among the people. The demand for the cost-effective diagnostic test with the increased accuracy level is expected to drive the growth of the rapid antigen testing market.

Apart from drivers, there are some factors which can restrain the growth of rapid antigen testing market such as lack of awareness regarding the newer rapid antigen test. The false-negative result can hamper the growth of the rapid antigen testing market.

Rapid Antigen Testing Market: Overview

Based on the techniques, the immunosorbent assay is expected to be the most preferred technique in the rapid antigen testing market due to its high efficiency. Based on the application, autoimmune diseases are expected to be diagnosed most in the rapid antigen testing market, followed by sexually transmitted diseases. Based on the end-user, hospitals are expected to be the most profitable segment in the global rapid antigen testing market.

Rapid Antigen Testing Market: Region-wise Outlook

North America is expected to dominate the global rapid antigen testing market, owing to the prominent technological advancements and innovations in diagnostic techniques. North America to be followed by Europe, owing to the increasing incidence of liver diseases.

Increasing population and rising prevalence of autoimmune diseases in developing region like Asia-Pacific is expected to further push the global rapid antigen testing market growth over the forecast period.

The demand for advanced medical infrastructure is further likely to drive the growth of the rapid antigen testing market in these regions. The increase in healthcare expenditure is also expected to drive the growth of rapid antigen testing market in these regions.

Rapid Antigen Testing Market: Key Market Participants

Some of the market participants in the global rapid antigen testing market identified across the value chain include:

• Abbott Laboratories
• F. Hoffmann-La Roche AG
• Oxford BioMedica
• Affinity Biologicals, Inc.
• Epitope Diagnostics, Inc.
• Sino Biological, Inc.
• R-Biopharma AG
• Cell Biolabs, Inc
• Thermo Fisher Scientific
• Bio-Rad Laboratories Inc.

The report covers exhaust analysis on

• Rapid Antigen Testing Market Segments
• Rapid Antigen Testing Market Dynamics
• Market Size
• Supply & Demand
• Current Trends/Issues/Challenges
• Competition & Companies involved
• Technology
• Value Chain

Regional analysis includes

• North America (USA, Canada)
• Latin America (Mexico. Brazil)
• Western Europe (Germany, Italy, France, United Kingdom, Spain)
• Eastern Europe (Poland, Russia)
• Asia Pacific (India, ASEAN, Australia & New Zealand)
• China
• Japan
• Middle East and Africa (GCC Countries, S. Africa, Northern Africa)

Table of Content

• 1. Executive Summary
• 2. Industry Introduction, including Taxonomy and Market Definition
• 3. Market Trends and Success Factors, including Macro-economic Factors, Market Dynamics, and Recent Industry Developments
• 4. Global Market Demand Analysis and Forecast, including Historical Analysis and Future Projections
• 5. Pricing Analysis
• 6. Global Market Analysis and Forecast
  • 6.1. Technique
  • 6.2. Application
  • 6.3. End-User
• 7. Global Market Analysis and Forecast, By Technique
  • 7.1. Immunosorbent Assay
  • 7.2. Enzyme-linked Immunosorbent
  • 7.3. Precipitation Reaction
  • 7.4. Radioimmunoassay
  • 7.5. Agglutination Reaction
  • 7.6. Complement Fixation
• 8. Global Market Analysis and Forecast, By Application
  • 8.1. Sexually Transmitted Diseases
  • 8.2. Autoimmune Diseases
  • 8.3. Tropical Diseases
  • 8.4. Liver Diseases
• 9. Global Market Analysis and Forecast, By End-User
  • 9.1. Hospitals
  • 9.2. Specialty Clinics
  • 9.3. Diagnostic Centers
  • 9.4. Others
• 10. Global Market Analysis and Forecast, By Region
  • 10.1. North America
  • 10.2. Latin America
  • 10.3. Western Europe
  • 10.4. Asia Pacific
  • 10.5. China
  • 10.6. Japan
  • 10.7. Middle East and Africa
• 11. North America Sales Analysis and Forecast, by Key Segments and Countries
• 12. Latin America Sales Analysis and Forecast, by Key Segments and Countries
• 13. Western Europe Sales Analysis and Forecast, by Key Segments and Countries
• 14. Asia Pacific Sales Analysis and Forecast, by Key Segments and Countries
• 15. China Sales Analysis and Forecast, by Key Segments and Countries
• 16. Japan Sales Analysis and Forecast, by Key Segments and Countries
• 17. Middle East and Africa Sales Analysis and Forecast, by Key Segments and Countries
• 18. Sales Forecast by Technique, Application, and End-User for 30 Countries
• 19. Competition Outlook, including Market Structure Analysis, Company Share Analysis by Key Players, and Competition Dashboard
• 20. Company Profile
  • 20.1. Abbott Laboratories
  • 20.2. F. Hoffmann-La Roche AG
  • 20.3. Oxford BioMedica
  • 20.4. Affinity Biologicals, Inc.
  • 20.5. Epitope Diagnostics, Inc.
  • 20.6. Sino Biological, Inc.
  • 20.7. R-Biopharma AG
  • 20.8. Cell Biolabs, Inc
  • 20.9. Thermo Fisher Scientific
  • 20.10. Bio-Rad Laboratories Inc.